Research & Education

Early recall rates decline after second round of lung cancer screening.

The German Lung Cancer Screening Intervention Trial (LUSI) shows that the early repeat scan rate for suspicious findings decreased by more than 80% with the second and subsequent low-dose computed tomography (LDCT) screens, but emphasizes the need to have an organized screening program with the baseline scan available for comparison.

Concurrent chemoradiation treatment at high-volume facilities improves survival for non-small cell lung cancer patients.

Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.

Online education tool helps bridge gaps in therapeutic decision-making for advanced NSCLC.

A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient’s molecular and clinical characteristics by providing feedback from an expert panel.

Mesothelioma in young people and women in southern Nevada likely the result of asbestos in the environment

Malignant mesothelioma has been found at higher than expected levels in women and in individuals younger than 55 years old in the southern Nevada counties of Clark and Nye, likewise in the same region carcinogenic mineral fibers including actinolite asbestos, erionite, winchite, magnesioriebeckite and richterite were discovered. These data, published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer, suggest that these elevated numbers of malignant mesothelioma cases are linked to environmental exposure of carcinogenic mineral fibers.

The Dutch-Belgian NELSON lung cancer screening trial results are inferable for the general high-risk population.

Results of the NELSON lung cancer screening trial using low dose computed tomography (LDCT) can be used to predict the effect of population-based screening on the Dutch population even though there were slight differences in baseline characteristics of participants in the control arm versus eligible non-participants.

Not all EGFR mutations are the same when it comes to therapy for non-small cell lung cancer.

Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common “classical” EGFR mutations. However, as not all rare mutations are the same, testing and therapy may need to be evaluated for each individual mutation.